Dapansutrile, an oral selective NLRP3 inflammasome...

The Lancet Rheumatology 2020 / 05 Vol. 2; Iss. 5

Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial

Klück, Viola, Jansen, Tim L Th A, Janssen, Matthijs, Comarniceanu, Antoaneta, Efdé, Monique, Tengesdal, Isak W, Schraa, Kiki, Cleophas, Maartje C P, Scribner, Curtis L, Skouras, Damaris B, Marchetti
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
2
Journal:
The Lancet Rheumatology
DOI:
10.1016/S2665-9913(20)30065-5
Date:
May, 2020
File:
PDF, 523 KB
2020
Conversion to is in progress
Conversion to is failed